Dr. Steven E. Finkelstein M.D., DABR, FACRO, received his M.D. from the University of Michigan in 1997 graduating cum laude eruditions causa. He joined the National Cancer Institute (NCI), National Institutes of Health (NIH) as Clinical Associate in 1999 and completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship in 2004. Dr. Finkelstein has been recognized as a Castle Connolly Top Doctor for five years in a row.
Dr. Steven E. Finkelstein M.D., DABR, FACRO, received his M.D. from the University of Michigan in 1997 graduating cum laude eruditions causa. He joined the National Cancer Institute (NCI), National Institutes of Health (NIH) as Clinical Associate in 1999 and completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship in 2004. Dr. Finkelstein has been recognized as a Castle Connolly Top Doctor for five years in a row.
The reviews listed below were collected independently of Associated Medical Professionals through rater8. Each review represents an authentic and verified patient experience.
He is very easy to talk with and is professional .Doctor Finkelstein shows confidence and compassion the way he explains the patient symptoms.
Dec-2024
AMP: Syracuse, NY
1226 East Water Street Syracuse, NY 13210
Dr. Steven E. Finkelstein M.D., DABR, FACRO, received his M.D. from the University of Michigan in 1997 graduating cum laude eruditions causa. He joined the National Cancer Institute (NCI), National Institutes of Health (NIH) as Clinical Associate in 1999 and completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship in 2004. Following completion of an additional radiation oncology residency, Dr. Finkelstein was selected as Chief Resident in Radiation Oncology at Moffitt Cancer Center/University of South Florida. In 2011, he was recruited to join the 21C Translational Research Consortium (TRC) and was appointed its National Director. In 2014, he was promoted to 21C Chief Science Officer. In 2017, he returned to Florida to serve as Cancer Director of Bay Regional Cancer Center at AUI. In 2019, Dr. Finkelstein joined the US Oncology Network at Florida Cancer Affiliates to continue advancing patient access to novel, advanced cancer care.
Dr. Finkelstein has a special interest in the study and patient care and research of a variety of cancers, using radiation driven, and personalized systemic therapy. Accordingly, he holds three International patents in the field of cutting edge technologies.
Dr. Finkelstein has given national and international lectures, published numerous professional journal articles and written book chapters, resulting in over 11,000 literature citations with an H-Index of 42. Additionally, he is renowned in bladder, kidney and testicular cancer as well as lung, breast and skin cancers which he also treats at A.M.P. He also serves on the editorial board of key international journals, including the American Society of Clinical Oncology (ASCO) as the ASCO Associate Editor for Immunotherapy.
For these contributions to patients, Dr. Finkelstein was one of the youngest physicians to receive accelerated fellowship in the American College of Radiation Oncology (ACRO) in 2017 and elected to the ACRO Board of Chancellors and Chair of Education in 2018.
Dr. Finkelstein has been recognized as a Castle Connolly Top Doctor for five years in a row.
He is very easy to talk with and is professional .Doctor Finkelstein shows confidence and compassion the way he explains the patient symptoms.